leisure time -WSS

leisure time

author：hotspot 2025-09-30 00:09:04 - browse：5

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Children’s Hospital revives plan for pedestrian bridge

WSS

Medicare isn't yet testing food as medicine

CDC panel: People 65 and older should get a Covid spring booster shot

Dogs on Prozac: What pet anti

Health care needs a new profession: neuroimaging counseling

Orangutan used medicinal plant to treat wound, first time ever seen

NEJM study measures Covid brain fog, impact on IQ

leisure time

leisure time

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

H5N1 bird flu found in pasteurized milk: what we know

Tori Bowie and the unacceptable rates of Black maternal death

Why does health care cost so much? A reading guide

What does generative AI mean for health care? We asked experts

Key Senate committee drafts bipartisan bill to stem drug shortages

Trump demands the U.S. pay no more for drugs than other countries … again

Diversity in clinical trials starts with building trust, experts say

Heart attack and stroke risk calculators need revising

MultiPlan and major insurers sued for alleged medical price

focus

H5N1 bird flu found in pasteurized milk: what we know

'Vaccine

CDC panel: People 65 and older should get a Covid spring booster shot

Redefining sustainability for the pharmaceutical industry

Change Healthcare cyberattack shows risk of industry consolidation

Redefining sustainability for the pharmaceutical industry

explore

knowledge

leisure time

knowledge